DEVELOPMENT OF A NOVEL ANTI-MULTIPLE MYELOMA CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY

Chuck Hay*, Mary Faber, Kemi Adeyanju, Jeffrey Medin. Medical College of Wisconsin, Wauwatosa, WI, USA

Background
Multiple myeloma is a cancer of plasma cells, wherein the plasma cells begin outgrowing and even suppressing the growth of normal hematopoietic-lineage cells in the blood marrow. It is estimated that nearly 35,000 new cases of multiple myeloma will be diagnosed each year, and over 12,000 individuals will die from multiple myeloma in 2021. The current overall 5-year survival rate of 54% stresses the need for alternative treatment strategies. A chimeric antigen receptor T cell (CAR-T) therapy that targets multiple myeloma surface proteins may have the potential to improve this survival rate.

Methods
A commonly associated multiple myeloma antigen was selected, and the extracellular domain of the protein was expressed in an Expi293 cell culture system. The multiple myeloma protein was expressed with and purified by a Hisx6 tag. The purified protein was used to pan a specific scFv phage display library that was generated uniquely for our lab from multiple blood donors. Several clones were identified and sequenced. One clone was selected and verified to be capable of binding the multiple myeloma antigen via ELISA. This anti-multiple myeloma scFv was then subcloned into CAR-T plasmids. This is a second-generation CAR-T using a 4-1BB co-stimulator domain and a CD3ζ intracellular signaling domain was used for this therapy. Further, a cell-fate control gene, LNGFRATmpk, was added to the plasmid to combat potential graft versus host disease. CAR-T and lentivirus (LV) plasmids were transfected into HEK cells to produce anti-multiple myeloma CAR-T LV.

Results
The anti-multiple myeloma CAR LV was transduced into HEK cells and titred via qPCR, which showed the LV prep produced 3.1E8 IU/ml. qPCR also showed there to be 0.407 vector copies per cell on average when using an MOI of 3. Our CAR-T LV was then used to transduce Jurkat cells at an MOI of 3. Using anti-Fab and anti-protein L antibodies, the transduced cells were shown to be expressing the anti-multiple myeloma CAR-T by flow cytometry. After confirming successful transduction and expression, transduced Jurkats (and controls) were co-cultured with multiple myeloma cell lines and incubated for 24 hours. ELISA testing for IFN-γ was performed on the resulting supernatants; specific engagement was demonstrated.

Conclusions
These results show that our anti-multiple myeloma CAR is successfully expressed and is functional. Our future goal is to successfully transduce our anti-multiple myeloma CAR LV into primary T cells and test for functionality in these cells before transitioning into in vivo models.

http://dx.doi.org/10.1136/jitc-2021-SITC2021.855